Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pediatric Arthritis Study of Certolizumab Pegol (PASCAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01550003
Recruitment Status : Recruiting
First Posted : March 9, 2012
Last Update Posted : February 21, 2021
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
UCB Pharma ( UCB BIOSCIENCES GmbH )

Brief Summary:
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

Condition or disease Intervention/treatment Phase
Polyarticular-course Juvenile Idiopathic Arthritis (JIA) Drug: Certolizumab Pegol (CZP) Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:

The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the study participant's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region). A Final Visit will be conducted 12 weeks after last dose of study medication. Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards. All patients will receive active treatment with Certolizumab Pegol. The dose will depend on actual weight. Home dosing will be allowed between study visits.

If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 193 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Actual Study Start Date : March 2012
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Certolizumab Pegol
Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
Drug: Certolizumab Pegol (CZP)

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Reduced CZP regimen (after implementation of protocol amendments 4 and 5):

  • 10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
Other Name: Cimzia

Drug: Certolizumab Pegol (CZP)

CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.

CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.

Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.

Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):

  • 10 to < 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
  • 20 to < 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
  • ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
Other Name: Cimzia




Primary Outcome Measures :
  1. Certolizumab Pegol (CZP) Plasma Concentration level at Week 16 [ Time Frame: Week 16 ]
    Certolizumab Pegol (CZP) Plasma Concentration level is measured in μg/mL.

  2. Certolizumab Pegol (CZP) Plasma Concentration level at Week 48 [ Time Frame: Week 48 ]
    Certolizumab Pegol (CZP) Plasma Concentration level is measured in μg/mL.

  3. Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 16 [ Time Frame: Week 16 ]
  4. Anti-Certolizumab Pegol (anti-CZP) Antibody level at Week 48 [ Time Frame: Week 48 ]
  5. Incidence of serious treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From Baseline (Week 0) up to the Final Visit (12 weeks after final dose of CZP) ]

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

    • Results in death
    • Is life-threatening
    • Requires in patient hospitalization or prolongation of existing hospitalization
    • Is a congenital anomaly or birth defect
    • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

  6. Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of the Investigational Medicinal Product (IMP) during the study [ Time Frame: From Baseline (Week 0) up to the Final Visit (12 weeks after final dose of CZP) ]
    An Adverse Event (AE) is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.


Secondary Outcome Measures :
  1. American College of Rheumatology Pediatric 30 % (PedACR30) Response at Week 16 [ Time Frame: Week 16 ]

    The assessment of the PedACR30 at Week 16 compared to Baseline is based on a 30 % or greater improvement in at least 3 of the 6 core set measures with no more than 1 of the remaining worsened by >30 %.

    The 6 core set measures are:

    • Number of joints with active arthritis (joints with swelling not due to deformity or inactive synovitis, or joints with limitation of motion with pain, tenderness, or both)
    • Number of joints with limitation of range of motion
    • Physician's Global Assessment of Disease Activity (VAS)
    • CHAQ completed by parent or caregiver
    • Parent's Global Assessment of Overall Well-Being (VAS)
    • Acute phase reactant (CRP)

  2. American College of Rheumatology Pediatric 50 % (PedACR50) Response at Week 16 [ Time Frame: Week 16 ]

    The assessment of the PedACR50 at Week 16 compared to Baseline is based on a 50 % or greater improvement in at least 3 of the 6 core set measures with no more than 1 of the remaining worsened by >30 %.

    The 6 core set measures are:

    • Number of joints with active arthritis (joints with swelling not due to deformity or inactive synovitis, or joints with limitation of motion with pain, tenderness, or both)
    • Number of joints with limitation of range of motion
    • Physician's Global Assessment of Disease Activity (VAS)
    • CHAQ completed by parent or caregiver
    • Parent's Global Assessment of Overall Well-Being (VAS)
    • Acute phase reactant (CRP)

  3. American College of Rheumatology Pediatric 70 % (PedACR70) Response at Week 16 [ Time Frame: Week 16 ]

    The assessment of the PedACR70 at Week 16 compared to Baseline is based on a 70 % or greater improvement in at least 3 of the 6 core set measures with no more than 1 of the remaining worsened by >30 %.

    The 6 core set measures are:

    • Number of joints with active arthritis (joints with swelling not due to deformity or inactive synovitis, or joints with limitation of motion with pain, tenderness, or both)
    • Number of joints with limitation of range of motion
    • Physician's Global Assessment of Disease Activity (VAS)
    • CHAQ completed by parent or caregiver
    • Parent's Global Assessment of Overall Well-Being (VAS)
    • Acute phase reactant (CRP)

  4. American College of Rheumatology Pediatric 90 % (PedACR90) Response at Week 16 [ Time Frame: Week 16 ]

    The assessment of the PedACR90 at Week 16 compared to Baseline is based on a 90 % or greater improvement in at least 3 of the 6 core set measures with no more than 1 of the remaining worsened by >30 %.

    The 6 core set measures are:

    • Number of joints with active arthritis (joints with swelling not due to deformity or inactive synovitis, or joints with limitation of motion with pain, tenderness, or both)
    • Number of joints with limitation of range of motion
    • Physician's Global Assessment of Disease Activity (VAS)
    • CHAQ completed by parent or caregiver
    • Parent's Global Assessment of Overall Well-Being (VAS)
    • Acute phase reactant (CRP)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2)
  • Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2)
  • Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA)
  • Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline
  • Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment)
  • If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response
  • If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose

Exclusion Criteria:

  • Study participant has previously been exposed to more than 2 biologic agents
  • Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug
  • Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer
  • Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
  • Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not)
  • Study participant has a history of systemic JIA, with or without systemic features
  • Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication
  • Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related)
  • Study participant has active uveitis or a history of active uveitis within the preceding 6 months
  • Study participant has current, chronic or recurrent clinically significant infections
  • Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening [Visit 1]), had a recent (within the 6 months prior to Screening [Visit 1]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01550003


Contacts
Layout table for location contacts
Contact: UCB Cares +1 844 599 2273 UCBCares@ucb.com

Locations
Show Show 47 study locations
Sponsors and Collaborators
UCB BIOSCIENCES GmbH
PRA Health Sciences
Investigators
Layout table for investigator information
Study Director: UCB Cares +1 844 599 2273 (UCB)
Layout table for additonal information
Responsible Party: UCB BIOSCIENCES GmbH
ClinicalTrials.gov Identifier: NCT01550003    
Other Study ID Numbers: RA0043
First Posted: March 9, 2012    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
URL: https://vivli.org
Keywords provided by UCB Pharma ( UCB BIOSCIENCES GmbH ):
Cimzia
JIA
Polyarticular
Oligoarticular
Enthesitis-related-Arthritis
Juvenile Idiopathic Arthritis
Juvenile Psoriatic Arthritis
Certolizumab Pegol
PASCAL
CDP870
Additional relevant MeSH terms:
Layout table for MeSH terms
Certolizumab Pegol
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents